Claturafenib

**Semantic type:** Organic Chemical|Pharmacologic Substance

**Definition:** An orally bioavailable class 1 and 2 inhibitor of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, claturafenib selectively binds to and inhibits the activity of class 1 and 2 BRAF alterations. This inhibits the proliferation of tumor cells which express these BRAF alterations. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases.

**Synonyms:** - ARRY 440 - ARRY-440 - ARRY440 - BRAF Inhibitor PF-07799933 - CLATURAFENIB - PF 07799933 - PF-07799933 - PF07799933